Olympus To Cut 2,000 Jobs, Revises Guidance As FDA Inspections Weigh On Q3
Olympus released its Q3 2025 earnings on Feb. 13, lowering its full-year revenue outlook by 2% on a constant currency basis. While the company acknowledged continued pressure in the US, management said it expects performance to rebound in Q4.
Medtech Insight - February 19, 2026

Medtronic Wins FDA Clearance For Stealth AXiS, Targets Spine Robotics Growth
The Stealth AXiS system is designed as an integrated platform that combines robotics, surgical planning and navigation into a single solution for spine procedures.
Medtech Insight - February 19, 2026

AI-Native Software Offers Beauty Industry Automated Regulatory Compliance, R&D Assistance
IRI-Sys’s AI-native software helps brands reduce the time involved in developing products so they can bring beauty products to market faster, while helping manufacturers enhance efficiency, ensure quality and scale manufacturing capabilities.
HBW Insight - February 19, 2026

Telehealth Company Hims & Hers To Acquire Eucalyptus In A Deal Up To $1.15Bn
Hims&Hers announced plans to acquire digital health company Eucalyptus for up to $1.15bn.
Medtech Insight - February 19, 2026

Executives On The Move: Interim CEO Takes Helm At Sanofi Ahead Of New Chief from Merck KGaA
Other recent moves in the industry include changes at the top at Helus Pharma and Longeveron, plus four companies get a new chief medical officer.
Scrip - February 19, 2026

Haleon: Prevention Extends to Oral Care, With £19bn Savings Possible in the UK
New data from Haleon shows that untreated tooth decay costs the UK £18.9bn, strengthening the case for a national focus on preventive oral care. The firm is also expanding its Sensodyne range to meet growing demand for products that combine whitening with sensitivity protection.
HBW Insight - February 19, 2026

Zealand Sets Out Strategy To Build ‘Generational Biotech’
A pivotal year lies ahead for its Roche-partnered obesity hopeful petrelintide.
Scrip - February 19, 2026

Regulatory Recap: India Boosts Biosimilar Development With A $1bn Investment
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - February 19, 2026

Execs On The Move: February 9–13, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - February 19, 2026

Latest FDA Biosimilar Nod Pushes Accord Towards 2030 Target
Accord Biopharma’s US FDA approval for a filgrastim biosimilar rival to Neupogen takes it a step closer to realizing its ambition of launching 20 biosimilars by 2030.
Generics Bulletin - February 19, 2026

Can Outlook Break The Cycle With Fresh FDA Meeting On Ophthalmic Bevacizumab?
After multiple knockbacks from the US FDA over its Lytenava ophthalmic formulation of bevacizumab, Outlook Therapeutics is hoping to resolve issues with the agency. It said the latest complete response letter was “inconsistent” with the BLA's evidence and “unexpected” after earlier FDA advice.
Generics Bulletin - February 19, 2026

UK Industry Fires Warning Shots Over Cost Burden, Support Levels And Over-Regulation In Market
The latest annual UK ABHI survey of medtech industry sentiment on market access, regulatory hurdles and pathways for innovation reveals polarized views and levels of frustration among manufacturers who face ever higher compliance workloads.
Medtech Insight - February 19, 2026

BioVersys And GSK See Lifesaving Potential And Commercial Future For New TB Drug
Phase II results have boosted hopes for alpibectir, which the partners believe could transform pulmonary tuberculosis and meningitis tuberculosis treatment, and earn up to $400m a year.
Scrip - February 19, 2026

MSD’s Groom On An AI-Assisted Pipeline, Foundation Models
MSD’s Chief AI Officer talks about how AI is reshaping R&D, enabling the company to double its molecules in discovery, foundational models and leading 'differently' in the age of AI.
Scrip - February 19, 2026

Burn Control And Subcutaneous Focus: OSE’s Bid To Reprice Its Science
When OSE Immunotherapeutics' board ousted CEO Nicolas Poirier in October 2025, it handed his successor a clear mandate: spend less, partner sooner and stop asking shareholders to wait.
In Vivo - February 19, 2026

Fresh Off Its Launch, Novartis’s Rhapsido Notches Phase III Win In Chronic Inducible Urticaria
Positive Phase III data for Rhapsido in chronic inducible urticaria adds regulatory momentum to what Novartis describes as a key growth driver within its immunology portfolio.
Scrip - February 19, 2026

Survey Of 21,000 US Consumers Provides Clear Profile On Value Of Making Drugs Available OTC
“Observed changes in use prevalence align with changes in regulatory status and availability, including medications” available Rx-only during a 2002 study, “available OTC during the current study period.”
HBW Insight - February 19, 2026

NextGate On Korean Biopharma’s Value Proposition For Investors
NextGate Partners’ managing partner shares his views on the biopharma investment and dealmaking environment in South Korea, along with the particular strengths of companies in the country and R&D areas of focus for this year.
Scrip - February 19, 2026

Stakeholders Urge US FDA To ‘Unlock’ Sunscreen Innovation Pipeline
Comments on the US Food and Drug Administration’s bemotrizinol proposed order were unanimously in favor of the measure, with some stakeholders taking the opportunity to encourage the agency to adopt additional sunscreen regulatory measures to speed up approval of new filters.
HBW Insight - February 19, 2026